Biodesix [BDSX] - Last Close: $1.59
Biodesix is up big on news of a successful private placement.
The data-driven diagnostics company announced this morning that it had successfully entered into private placement agreements with a consortium of investors, including three board members and existing shareholders, to issue and sell more than 6.5 million shares of its stock.
The investors paid $1.79 apiece to acquire the newly-minted shares, equivalent to the closing price on April 7th.
Altogether, the price tag for the new shares came out to about $11.7 million, according to a Biodesix's regulatory filing.
BDSX is trading actively with a 50.9% gain.
Biocardia [BCDA] - Last Close: $2.15
News of a new drug approval is lifting shares of Biocardia in today's premarket.
This morning, the clinical-stage regenerative medicine company announced the US Food & Drug Administration approved the firm's Investigational New Drug (IND) application for BCDA-04.
The FDA decision clears the way for Biocardia to begin first-in-human Phase I/II trials in adult patients recovering from Acute Respiratory Distress Syndrome resulting from COVID-19.
Biocardia says it expects to initiate the trial sometime in the third quarter.
BCDA is up 54.9% on active trading volume following the premarket announcement.
